Not Yet Recruiting
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
NCT07545044
- Conditions
- Breast Diseases, Breast Neoplasms, HER2-positive Recurrent or Metastatic Breast Cancer, +4 more
- Locations
-
Not specified